DC371739
DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia[1][2].
Product Specifications
CAS Number
2135765-21-6
UNSPSC
12352005
Target
ANGPTL; PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/dc371739.html
Purity
95.56
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
OCN1C2=C(C3=C1CN4CCC5=CC(OCC6=CC=CC=C6)=C(C=C5C4C3)OC)C=C(OC)C=C2
Molecular Formula
C29H30N2O4
Molecular Weight
470.56
References & Citations
[1]Bao X, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) : from bench to bedside. Signal Transduct Target Ther. 2024 Jan 8;9 (1) :13.|[2]Wang J, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial. Cell Metab. 2022 May 3;34 (5) :667-680.e6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
